A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Joel M. Gelfand, Daniel B. Shin, Kristina Callis Duffin, April W. Armstrong, Andrew Blauvelt, Stephen K. Tyring, Alan Menter, Scott Gottlieb, Benjamin N. Lockshin, Eric L. Simpson, Farid Kianifard, Rajendra Prasad Sarkar, Elisa Muscianisi, Jennifer Steadman, Mark A. Ahlman, Martin P. Playford, Aditya A. Joshi, Amit K. Dey, Thomas J. Werner, Abass AlaviNehal N. Mehta

Research output: Contribution to journalArticle

Abstract

Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of cardiovascular events and mortality. Secukinumab selectively neutralizes IL-17A and has reported high efficacy with a favorable safety profile in various psoriatic disease manifestations. Subsequent to the 12-week randomized, placebo-controlled, double-blind treatment period, patients with moderate-to-severe psoriasis received secukinumab for 40 weeks. Vascular inflammation using 18F-2-fluorodeoxyglucose–positron emission tomography/computed tomography imaging and blood-based cardiometabolic was assessed at week 0, 12, and 52. The difference in change in aortic inflammation from baseline to week 12 for secukinumab (n = 46) versus placebo (n = 45) was –0.053 (95% confidence interval = –0.169 to 0.064; P = 0.37). Small increases in total cholesterol, low-density lipoprotein, and low-density lipoprotein particles, but no changes in markers of inflammation, adiposity, insulin resistance, or predictors of diabetes, were observed with secukinumab treatment compared with placebo. At week 52, reductions in TNF-α (P = 0.0063) and ferritin (P = 0.0354), and an increase in fetuin-A (P = 0.0024), were observed with secukinumab treatment compared with baseline. No significant changes in aortic inflammation or markers of advanced lipoprotein characterization, adiposity, or insulin resistance were observed with secukinumab treatment compared with baseline. Secukinumab exhibited a neutral impact on aortic vascular inflammation and biomarkers of cardiometabolic disease after 52 weeks of treatment.

Original languageEnglish (US)
JournalJournal of Investigative Dermatology
DOIs
StateAccepted/In press - Jan 1 2020

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Gelfand, J. M., Shin, D. B., Duffin, K. C., Armstrong, A. W., Blauvelt, A., Tyring, S. K., Menter, A., Gottlieb, S., Lockshin, B. N., Simpson, E. L., Kianifard, F., Sarkar, R. P., Muscianisi, E., Steadman, J., Ahlman, M. A., Playford, M. P., Joshi, A. A., Dey, A. K., Werner, T. J., ... Mehta, N. N. (Accepted/In press). A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2020.01.025